Skip To Content

News & Events

Given the activity level of our attorneys, we are confident in showcasing the various matters that our clients have given us the privilege to work on and approved to post here.

Posts

  • September 13 2019

    Experience Investment Corp. announced the closing of its initial public offering in the amount of $250,000,000.  EG&S acted as counsel to Experience.

  • September 12 2019

    Jennifer D. Silverman, a member of the Firm, interviewed Nicole Liebman, Esq. General Counsel of WithumSmith+Brown PC, for High Performance Counsel, a media company focusing on innovation in the legal industry (highperformancecounsel.com).  The interview was the first in the #raisethevolume series, which amplifies the accomplishments, practices, viewpoints and needs of some of the brightest and best in the modern legal industry.  The interview can be accessed at:   https://highperformancecounsel.com/raisethevolume_nicole-liebman/

  • September 10 2019

    New Providence Acquisition Corp. announced the closing of its initial public offering in the amount of $200,000,000.  EG&S acted as counsel to the underwriter.

  • September 10 2019

    Arcadia Biosciences, Inc. announced the closing of their Registered Direct offering in the amount of $10,000,013.  EG&S acted as counsel to the Placement Agent.

  • September 09 2019

    Capstone Turbine Corporation announced the closing of their Registered Direct offering in the amount of $5,100,000.  EG&S acted as counsel to the Placement Agent.

  • September 04 2019

    OncoCyte Corporation (“OncoCyte”) announced that it entered into a definitive agreement to acquire a 25% interest in Razor Genomics Inc. (“Razor”), with the right to acquire the remainder of Razor thereafter (and OncoCyte is obligated to do so upon certain milestones being reached by Razor).   On September 30, 2019, OncoCyte closed its initial investment in Razor and acquired shares of Razor preferred stock representing 25% of the outstanding equity of Razor.  EGS acted as counsel to OncoCyte.

  • September 04 2019

    PolyPid Ltd., a clinical-stage biopharmaceutical company in Israel, conducted the final closing of its Series E-1 preferred share private placement offering which raised gross proceeds of $50,000,000.  EG&S acted as counsel to National Securities Corporation, the U.S. placement agent for the offering.

  • August 27 2019

    Seelos Therapeutics, Inc. announced the closing of their Registered Direct offering in the amount of $6,712,500.  EG&S acted as counsel to the Placement Agent.

“It’s with genuine appreciation to all of our clients that we are in a position to achieve and maintain our leadership position in so many areas.”